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Abstract
Background: People living with HIV (PLWH) who have positive tuberculin skin tests (TST) benefit from isoniazid preventive
therapy (IPT) whereas those testing TST-negative do not. Revised World Health Organization guidelines explicitly state that
assessment of TST is not a requirement for initiation of IPT. However, it is not known what proportions of patients will
benefit from IPT if implemented without targeting according to TST status. We therefore determined the proportions of
PLWH who test TST-positive.
Methodology/Principal Findings: We systematically reviewed the literature published between January 1990 and February
2012 to determine the proportions of patients without active tuberculosis attending HIV care services in low and middle-
income countries who tested TST-positive ($5 mm induration). Proportions were also determined for different CD4 count
strata. Data from 19 studies with 9,478 PLWH from sub-Saharan Africa, Asia and Central and South America were
summarized. The vast majority were not receiving antiretroviral therapy (ART). A sub-analysis was conducted of 5 studies
(5,567 subjects) from high TB prevalence countries of PLWH with negative TB screens attending HIV care and treatment
settings for whom CD4 stratified data were available. The median proportion of PLWH testing TST-positive overall was
22.8% (range, 19.5–32.6%). The median (range) proportions with CD4 cell counts of ,200, 200–499 or $500 cells/mL who
tested positive were 12.4% (8.2–15.3%), 28.4% (20.1–36.9%) and 37.4% (31.3–56.3%), respectively. Heterogeneity in the data
precluded calculation of pooled summary estimates.
Conclusions/Significance: In most settings, if IPT is administered to PLWH pre-ART without assessment of TST status, only a
minority of those treated are likely to benefit, especially among those with the lowest CD4 cell counts. This may be
inefficient use of resources and cost-effectiveness analyses should take this into account. Local knowledge of TST response
rates may help inform policies. New simple means of identifying those who will benefit from IPT are needed to permit
appropriate targeting of this intervention.
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Introduction
HIV-associated tuberculosis (TB) remains a substantial chal-
lenge to global health [1], accounting for an estimated 12% (1.1
million) of the overall TB caseload and one quarter (0.35 million)
of HIV/AIDS deaths worldwide [2]. Four main programme
interventions are recommended to prevent HIV-associated TB
[3]. These include scale-up of antiretroviral therapy (ART) [4]
used in combination with intensified case finding, isoniazid
preventive therapy [IPT] and infection control, the latter
interventions being referred to by the acronym the ‘three I’s
strategy’ [5]. However, a large majority of cases are in sub-
Saharan Africa where the capacity to deliver the needed control
interventions is limited [6]. For many years, implementation of
IPT in particular has been very poor [7].
A meta-analysis of placebo-controlled trials reported that IPT in
people living with HIV (PLWH) conferred an overall risk
reduction of 33% (95%CI, 13–49%) [8]. A beneficial effect was
only observed among those who tested tuberculin skin test (TST)
positive in whom there was a substantially greater risk reduction of
64% (95%CI, 39–78%). In contrast, no benefit was observed
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among PLWH (n = 2,490) in these trials with negative or anergic
TST reactions [8]. Based on this evidence, WHO guidelines
between 1998 and 2010 emphasized the main use of IPT as being
for prophylaxis of those who are TST-positive [9].
With low uptake of IPT and recognition that the process of TST
assessment was a major programmatic stumbling block, the 2011
revision of the WHO IPT guidelines made a strong explicit
recommendation that ‘‘TST is not a requirement for initiating IPT
in people living with HIV’’ although it ‘‘can be used where
feasible’’ [10]. Eliminating the need for assessment of TST status
has simplified implementation substantially. However, this means
that the intervention is no longer targeted at those who will derive
benefit and a small proportion of PLWH who are unlikely to
derive benefit might be harmed. The cost-effectiveness of IPT with
or without use of TST assessment in a clinical population is likely
to be strongly associated with the prevalence of positive TST tests.
We therefore conducted this systematic review.
The proportion of PLWH testing TST-positive is likely to be
associated with the prevalence of TB in the local community, the
prevailing force of infection, social mixing patterns and the clinical
population sampled. Prevalence also increases with age [11] but
may be attenuated in those with suppression of cell-mediated
immune responses. Progressive CD4 cell count loss that charac-
terizes HIV progression is strongly associated with increasing
proportions of anergic TST responses [12]. We therefore
conducted this systematic literature review and meta-analysis to
determine the proportion of PLWH in HIV care and treatment
settings who test TST positive and how this proportion varies
across a range of CD4 cell count strata.
Methods
Systematic Search Strategy
We conducted the search and review process according to a
predefined protocol and the study conformed to the PRISMA
statement checklist [13]. Embase, Global Health, Medline and
Web of Science were searched for potentially relevant citations
using a defined search strategy (Table S1). The search included
articles published in English between January 1st 1990 and
February 5th 2012, covering the majority of the epidemic [14].
Initial searches found no relevant data published before this
period. The bibliographies of review articles on interferon-c-
release assays were specifically searched for additional articles.
Abstracts from the World Conference on Lung Health of the
International Union Against Tuberculosis and Lung Disease
(IUATLD) published between 2004 and 2011 were searched by
hand for additional relevant citations.
Citations identified through the search process were compiled
into Endnote X4 and duplicates removed. Titles and abstracts
were screened for eligibility according to pre-defined inclusion and
exclusion criteria and full-texts were reviewed for eligibility by
ADK and SDL. The authors of eligible studies were contacted as
required to clarify or modify the stratification of their data by CD4
cell count.
A study was eligible for inclusion if it was conducted in a low-
income or middle-income country (as defined by the World Bank
list of economies current on 1st July 2011) [15]; the study subjects
were PLWH aged 15 years or older; the study reported TST
results (positive if $5 mm induration) for individuals stratified into
at least two CD4 cell count strata (CD4 cell counts ,200 and
$200 cells/mL); data were reported on PLWH without evidence of
current active TB disease, and if the study contained 50 or more
subjects meeting the above criteria. If two eligible studies
presented overlapping samples, only the study with a larger
sample size was included. Studies using a two-step TST-testing
were excluded as this methodology is not used in public health
programmes in resource-limited settings.
Data from eligible studies were abstracted directly into a
structured Microsoft Excel spreadsheet. Study characteristics
recorded included title, authors, year of publication, study period,
study location, mean or median patient age, bacille Calmette et
Guerin (BCG) scar status, clinical setting, ART status, TST
methodology, inclusion of special populations or sub-groups and
the total number of PLWH with TST-positive and TST-negative
results stratified by CD4 counts (either using ,200 and $200
cells/mL or using ,200, 200–499 and $500 cells/mL).
Sub-analysis of Studies
For inclusion in a sub-analysis and potential meta-analysis, we
selected those studies in high TB prevalence settings which were of
sufficient size, were conducted among PLWH accessing HIV care
and treatment services and in whom active TB had been excluded.
This selection reflects the PLWH who are specified in WHO
guidelines as being the key targets for IPT [10]. High TB
prevalence was defined as an average $100 cases per 100,000
population using WHO estimates for the five-year period spanning
the study mid-point [7]. A minimum of 40 PLWH were required
in each CD4 cell count stratum to limit imprecision around
estimates (anticipated range, 10%–50% testing TST-positive).
Studies evaluating TB diagnostic assays or conducted in TB clinics
were excluded due to the likelihood for selection bias during
enrolment.
Two reviewers (ADK and SDL) assessed the quality of studies
using a graded checklist (Table S2). A study was scored ‘‘good
quality’’ if it received 70% or more of available points, ‘‘medium
quality’’ if it received between 50–69% and ‘‘lower quality’’ if less
than 50%. The primary outcome of interest for our study was the
proportion of PLWH who tested TST-positive among those in
each of the following CD4 cell count strata: ,200, 200–499 and
$500 cells/mL. Risk of bias in individual studies and across studies
was also assessed.
Data-analysis
All statistical analyses were conducted using STATA 10. The
proportions of PLWH testing TST-positive were calculated with
corresponding 95% confidence intervals (95% CI). These data
were stratified by geographic region, country TB prevalence
(,100, 100–249 or $250 cases per 100,000 population) and CD4
cell count (,200 and $200 cells/mL or ,200, 200–499 and $500
cells/mL). Findings were presented using forest plots. The median
and corresponding range of proportions of patients testing TST-
positive were calculated. I-squared statistics [16] were calculated to
assess the heterogeneity of the data stratified by CD4 cell count.
Results
Studies Included
Of 3,095 potentially relevant citations identified, 254 were
selected for full-text review (Figure 1). Ten publications initially
met inclusion criteria and nine others met inclusion criteria after
supplementary data were provided by study authors. Ten others
remained ineligible despite seeking supplementary data (Table S3).
The final group of eligible publications (n = 19) were published
between 1997 and 2011.
Of the studies included (n = 19), five were from sub-Saharan
Africa, four from South-East Asia, four from the Americas, three
from the Eastern Mediterranean two from the Western Pacific and
one from Europe (Table 1). A majority (n = 14; 74%) were
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conducted in high-prevalence TB countries (estimated TB
prevalence $100 cases per 100,000 population). The mean or
median age of study subjects ranged between 22 and 40 years, but
overall 90% of patients were from studies in which the mean or
median age was within the range 29–40 years. The methods used
for excluding active TB were reported by 13 (68%) studies but
were not standardised. All studies defined TST positivity using a
cut-off of $5 mm diameter of induration. Study quality was
assessed as high in six studies, medium quality in eight and lower
quality in five. Risks of bias in reporting the outcome of interest or
publication bias were considered to be low.
The proportions of PLWH receiving ART at the time of TST
assessment was reported by ten studies and two other studies pre-
dated national ART implementation and these were therefore
assumed to be ART-naı̈ve populations. Among these twelve
studies, the proportion of patients receiving ART ranged from 0 to
84% with a median of 5.4% (IQR, 0–32.5%).
The studies included a total of 9,478 subjects and 2,820 (29.8%)
of these had CD4 cell counts ,200 cells/mL and 6,658 (70.3%)
had counts of .200 cells/mL. In 16 studies the data were further
stratified, providing data from 4,034 subjects with CD4 counts of
200–499 cells/mL and 2,231 with counts of $500 cells/mL.
Proportions Testing TST-positive
The numbers and proportions of PLWH testing TST-positive
for each of the 19 studies are summarized (Table 2). The overall
median proportion testing TST positive was 26.0% (IQR, 20.6–
41.2%; range 11.0–57.6%). The proportions testing positive
stratified according to geographical region (Figure 2A) and
Figure 1. Selection of eligible studies containing data on the proportion of people living with HIV testing tuberculin skin test (TST)-
positive stratified by blood CD4 cell count.
doi:10.1371/journal.pone.0049928.g001
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Figure 2. Forest plot showing the proportions (%, 95%CI) of people living with HIV testing TST-positive in the all studies (n = 19)
with data grouped according to: a) geographical region; b) country TB prevalence (,100, 100–249 and $250 cases per 100,000
population) and c) CD4 cell count (,200 or $200 cells/mL).
doi:10.1371/journal.pone.0049928.g002
Proportion of People Living with HIV Testing TST+
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country TB prevalence (Figure 2B) were displayed in forest-plots.
The data were found to be heterogeneous and no clear
associations with either of these two variables were evident.
We next summarized the data stratified according to CD4 cell
count strata (Table 2). These data stratified by CD4 cell counts of
,200 cells/mL and $200 cells/mL were available for all 19 studies
included and are displayed in Figure 2C. Although there was
heterogeneity within these groups, the proportions testing TST-
positive tended to be higher among PLWH with CD4 cell counts
of $200 cells/mL (median 33.3%; IQR, 22.1–43.8%; range, 11.5–
59.9%) compared to those with CD4 cell counts ,200 cells/mL
(median 15.3%; IQR, 11.2–23.9%; range, 7.7–50.0%).
Sub-analysis of Studies
Of the 16 studies that provided TST data stratified by three
CD4 cell count strata (,200, 200–499 and $500 cells/mL), 5 also
fulfilled the additional criteria for inclusion in the meta-analysis
(Table 1). Four studies were scored as high quality and one
medium quality and they included 5,567 (58.7%) of the overall
9,478 PLWH in the review. The studies were from Senegal,
Uganda, Botswana, Mexico and Thailand and the average five-
year national TB prevalence estimates for these countries ranged
between 123 and 750 cases per 100,000 population. Mean age
ranged between 29 and 37 years. The proportion of PLWH
receiving ART at the time of TST assessment was low (range, 0–
12.4%) and most had evidence of BCG vaccination (Table 1).
Among subjects (n = 5,567) included in the analysis, 2,121 (38.1%)
had a CD4 cell count ,200 cells/mL, 2,353 (42.3%) a CD4 cell
count 200–499 cells/mL, and 1,093 (19.6%) a CD4 cell count
$500 cells/mL.
The median proportion testing TST-positive in these 5 studies
was 22.8% (range, 19.5–32.6%). These data are shown in a forest
plot stratified by CD4 cell count ,200 cells/mL, 200–499 cells/mL
and $500 cells/mL (Figure 3). The proportions testing TST-
positive differed between the three groups, with medians of 12.4%
(range, 8.2–15.3%), 28.4% (range, 20.1–36.9%) and 37.4% (range,
Figure 3. Forest plot showing the proportions (%, 95%CI) of people living with HIV testing TST-positive in studies (n = 5) included
in the meta-analysis with data grouped according to CD4 cell count strata (,200, 200–499 and $500 cells/mL). The median proportions
testing positive in these three groups were 12.4% (range, 8.2–15.3%), 28.4% (range, 20.1–36.9%) and 37.4% (range, 31.3–56.3%). The I2 statistics for
these three groups of data were 54.4% (P = 0.067), 84.2% (P,0.001) and 86.8% (P,0.001), respectively.
doi:10.1371/journal.pone.0049928.g003
Proportion of People Living with HIV Testing TST+
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31.3–56.3%), respectively. I-squared statistics showed significant
heterogeneity within each stratum, however, precluding the
calculation of pooled summary estimates.
Discussion
In this systematic review, we summarized data from 19 studies
that included 9,478 PLWH from low- and middle-income
countries in sub-Saharan Africa, Asia and Central and South
America. The median proportion of PLWH testing TST-positive
was 26.0% overall but with substantial heterogeneity (range, 11.0–
57.6%). Five of these studies (5,567 subjects) were selected for
inclusion in a sub-analysis on the basis of high country TB
prevalence, adequate study size and quality and inclusion of
PLWH without TB attending HIV care and treatment settings.
Among these studies, the median proportions of patients with CD4
cell count ,200 cells/mL, 200–499 cells/mL and $500 cells/mL
testing TST-positive were 12.4% (range, 8.2–15.3%), 28.4%
(range, 20.1–36.9%) and 37.4% (range, 31.3–56.3%), respectively.
Data heterogeneity, however, precluded calculation of pooled
summary estimates. These data indicate that in most settings,
implementation of IPT among PLWH without assessment of TST
status is likely to benefit a minority of patients across all CD4
count categories.
In resource-limited settings, assessment of TST status is the only
recommended means of identifying patients who are likely to
benefit from IPT [10]. However, this unfortunately presents a
substantial operational barrier to implementation. The test
requires a refrigerated supply of purified protein derivative and
sterile supplies. Health care workers must be trained to administer
the test and accurately read the result. In order to reduce loss to
follow-up after TST placement [17] such novel interventions as
training of community outreach auxiliaries in the reading of the
induration must be studied. Although interferon-c-release assays
give fewer false-positive results, there is no evidence that these are
any more predictive of IPT benefit and these tests are not
recommended for use in resource-limited settings [10,18].
Removal of the requirement for TST assessment simplifies
implementation of IPT and may thereby help catalyze scale-up of
IPT. However, this study suggests that overall only approximately
1 in 4 PLWH stand to benefit from IPT if implemented in an
untargeted way. Although this would save resources needed to
assess TSTs, this would be wasteful of both patient and scarce
health care resources used in treating and following-up large
numbers of PLWH who would derive no benefit. Cost-effective-
ness analyses suggest that use of IPT either in a targeted or
untargeted way is cost-effective compared to not implementing
IPT at all [19,20]. In South Africa, both strategies were estimated
to be equally cost-effective [20] whereas in Uganda targeting IPT
by TST status was more favourable in terms of incremental cost
per QALY gained [19]. Both studies used optimistic assumptions
about the duration of the benefit of IPT. As ART is increasingly
available in resource-constrained settings, cost effectiveness
analyses of IPT – including long-term IPT – in combination with
ART are urgently needed to better assess the potential public
health utility of these interventions.
Data from southern Africa increasingly suggest that because of
high prevailing rates of community TB transmission, benefit from
IPT is largely limited to the period within which it is taken [21–
23]. Thus, long-term IPT is now an option recommended by
WHO [10]. If IPT is to be increasingly used on a long-term basis,
TST assessment may be even more important as suggested by a
cost-effectiveness analysis from Botswana. In this study, provision
of IPT for 36 months to TST-positive individuals only was more
cost-effective than providing IPT without TST assessment or
providing IPT for 6 months only [24].
Concerns have been expressed about the risks of widespread use
of isoniazid monotherapy fuelling development of drug resistance.
There is no evidence of such an effect from data generated during
carefully conducted randomized controlled trials [25], and yet it is
unknown what risk would be associated with widespread
availability of isoniazid monotherapy within communities outside
the context of intervention trials. Since development of antimi-
crobial resistance is directly related to how much a drug is used,
limiting drug exposure to the minority of PLWH who are likely to
benefit would be prudent.
Isoniazid is well known to be associated with low rates of
hepatotoxicity and occasional deaths [26]. Consistent with
previous studies, rates in two large IPT trials in southern Africa
have recently reported rates of hepatotoxicity of approximately
0.1–1.0% [27,28]. Peripheral neuropathy may also be exacerbated
by isoniazid and can be disabling and significantly reduce the
quality of life. Although overall rates of toxicity are low and
mortality rare, these events cannot be ignored and they provide an
important argument against use of IPT in those who are TST-
negative.
There was great heterogeneity between studies in the propor-
tions testing TST positive. This observation suggests that
knowledge of TST responses in specific countries or settings may
help local decisions on the pros and cons of targeted or untargeted
IPT delivery. This heterogeneity may reflect both the local TB
epidemiology as well as study-related factors. The latter may
include study design, methodology used for TST assessment
(including dose of PPD), the accuracy with which this was done,
potential biases associated with non-return of patients for TST
assessment, the rigour with which TB was excluded and the
characteristics of the patients tested. While we have attempted to
broadly summarize these variables, it was not possible to precisely
define the role of each. Importantly, however, the mean or median
ages of PLWH included in the meta-analysis all fell within a
narrow range (29–37 years). It was notable that country TB
prevalence did not appear from the forest plots to be a more
dominant factor. This may be related to imprecision of TB
prevalence estimates, differences between national estimates and
prevalence in the specific communities studied or the fact that TB
exposure is related to cumulative exposure over the life-time of the
individual rather than current prevalence.
The proportions of positive TST results stratified by CD4 cell
count observed among the total group of 19 studies were very
similar to those found in the 5 studies that were selected for further
analysis, providing reassurance that study selection did not
introduce substantial bias. Moreover, many of the other studies
that were excluded from the systematic review also report that
between 22–25% of PLWH tested TST-positive [29–33] (Table
S3). Although we were unable to include the unpublished data
from the THRio study in Brazil, an earlier publication from this
study reported that 24.8% of 5,492 PLWH tested TST positive
[34]. The proportions testing positive may be higher in South
Africa where rates of TB transmission are very high [11].
However, although the two studies identified from South Africa
were not eligible for inclusion in the meta-analysis, data from
1,891 PLWH in neighbouring Botswana were included (Table 2).
These data help to rationalize prevention strategies that need to
be tailored according to subjects’ CD4 cell counts. As CD4 cell
counts decrease during the natural history of HIV infection, risk of
TB progressively increases [14]. However, at the same time, the
proportion of individuals who are TST-positive and who might
benefit from IPT paradoxically decreases. Thus, at low CD4 cell
Proportion of People Living with HIV Testing TST+
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counts, ART is the key intervention needed to reduce the risk of
death and to serve as the principal TB preventive intervention.
This decreases TB risk by 67% (95%CI, 61–73%) [35], provides
benefit regardless of TST status [21] and can be started without
the need for careful exclusion of active TB [36]. There is also
growing evidence of the TB preventive effect of ART at higher
CD4 cell counts .350 cells/mL [37]. During long-term ART,
however, TB incidence rates remain several times higher than
rates in the community despite good CD4 cell count recovery
[38,39]. Observational data suggest there is an additive effect by
using ART and IPT concurrently [21,34,35] and this has now
been confirmed by data from a randomised controlled trial [40].
ART induces recovery of TST responses [41,42] and so a greater
proportion of PLWH during long-term ART may benefit from
IPT compared to the proportion at baseline. Few PLWH in this
meta-analysis, however, were receiving ART and so this could not
be assessed. Studies defining the impact of IPT according to TST
status in patients receiving ART are needed as this may not
necessarily be the same as that observed in the pre-ART era [8].
Although it is being recommended that ART be started at
increasingly high CD4 cell counts, IPT might be prioritized for
PLWH prior to ART eligibility. Ideally HIV would be identified
early in the course of disease and all those testing TST-positive
would receive a course of IPT prior to becoming eligible for ART.
However, even in those with CD4 cell counts of $500 cells/mL,
less than two in five PLWH (37.4%) tested TST-positive. Use of
TST assessment (or a new alternative test) in such patients would
permit appropriate targeting of therapy and could substantially
reduce the numbers unnecessarily treated.
Strengths of this study include a comprehensive search strategy
which identified studies from diverse geographic regions with a
range of TB prevalence estimates. Large numbers of PLWH
overall and with a broad range of CD4 cell counts were included.
Weaknesses include the paucity of data from PLWH receiving
ART, the lack of availability of data from other large as yet
unpublished studies and the inability to precisely define the impact
of other potential variables. In addition, the reliability of TST
assessment could not be assessed and the methods for excluding
TB were not standardized. Heterogeneity in the data precluded
calculation of pooled summary estimates.
In conclusion, we found that a minority PLWH were TST-
positive, even in the highest TB prevalence settings, and that the
proportion testing positive was strongly associated with CD4 cell
counts. This factor may undermine the cost-effectiveness of use of
untargeted IPT. Local knowledge of TST response rates may help
inform policies. Operational research to improve TST implemen-
tation as well as development of new, simple means to identify
those who will benefit from IPT are urgently needed [43].
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